Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma.
Kobayashi Y, Yamada D, Kawai T, Sato Y, Teshima T, Yamada Y, Nakamura M, Suzuki M, Matsumoto A, Nakagawa T, Hosoi A, Nagaoka K, Karasaki T, Matsushita H, Kume H, Kakimi K.
Kobayashi Y, et al. Among authors: yamada y, yamada d.
Int J Oncol. 2020 Apr;56(4):999-1013. doi: 10.3892/ijo.2020.4975. Epub 2020 Feb 4.
Int J Oncol. 2020.
PMID: 32319571